HALOZYME THERAPEUTICS, INC. - Common Stock (HALO)

Q1 2022 13F Holders as of 31 Mar 2022

Type / Class
Equity / Common Stock
Shares outstanding
123,650,000
Total 13F shares
126,175,835
Share change
-1,207,384
Total reported value
$5,029,140,681
Put/Call ratio
20%
Price per share
$39.88
Number of holders
292
Value change
-$48,393,289
Number of buys
129
Number of sells
151

Institutional Holders of HALOZYME THERAPEUTICS, INC. - Common Stock (HALO) as of Q1 2022

As of 31 Mar 2022, HALOZYME THERAPEUTICS, INC. - Common Stock (HALO) was held by 292 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 126,175,835 shares. The largest 10 holders included BlackRock Inc., VANGUARD GROUP INC, Artisan Partners Limited Partnership, STATE STREET CORP, WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC, Invesco Ltd., JPMORGAN CHASE & CO, SNYDER CAPITAL MANAGEMENT L P, GEODE CAPITAL MANAGEMENT, LLC, and MACQUARIE GROUP LTD. This page lists 294 institutional shareholders reporting positions in this security for the Q1 2022 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.